Gaithersburg, MD, United States of America

Nazzareno Dimasi

USPTO Granted Patents = 12 

 

 

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Nazzareno Dimasi: Innovator in Combination Therapies

Introduction

Nazzareno Dimasi is a prominent inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of medicine, particularly in the development of innovative therapies. With a total of 12 patents to his name, Dimasi's work focuses on addressing complex medical challenges.

Latest Patents

Among his latest patents are groundbreaking inventions such as "Combination therapies using anti-pseudomonas PSL and PCRV binding molecules." This patent relates to combination therapies that utilize anti-Psl and PcrV binding molecules for the prevention and treatment of infections. Another notable patent is for "Pyrrolobenzodiazepine conjugates," which describes a conjugate formula wherein a modified antibody has at least one free conjugation site on each heavy chain.

Career Highlights

Nazzareno Dimasi is currently associated with Medimmune Limited, where he continues to push the boundaries of medical research and innovation. His work has been instrumental in developing therapies that can significantly improve patient outcomes.

Collaborations

Dimasi collaborates with talented individuals in his field, including Changshou Gao and Ryan Fleming. Their combined expertise fosters an environment of innovation and creativity, leading to advancements in therapeutic solutions.

Conclusion

Nazzareno Dimasi stands out as a key figure in the realm of medical inventions, with a focus on combination therapies that address critical health issues. His contributions are paving the way for future advancements in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…